Serum Biomarkers for Diagnosis Drug Resistance Tuberculosis: A review
Keywords:
Serum biomarkers; diagnosis; drug-resistant tuberculosis; reviewAbstract
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global health. Current gold-standard diagnostic methods, such as culture, GeneXpert, and line probe assays, facing limitations including high costs, long processing times, and reliance on sputum samples. These challenges have driven the search for serum biomarkers for diagnostic approach. Serum biomarkers offer the potential for rapid and scalable diagnosis, especially for patients unable to produce sputum. This review synthesizes findings on key serum biomarkers, categorizing them into cytokines, oxidative stress markers, metabolic indicators, lipids, and genetic elements such as long non-coding RNAs and miRNAs. These biomarkers highlight the complex immune, metabolic, and molecular adaptations in MDR-TB, offering enhanced diagnostic precision and treatment monitoring capabilities. Future prospects include the development of cost-effective assays, large-scale validation studies, and the integration of multi-biomarker panels with advanced computational tools
References
Lv H, Zhang X, Zhang X, Bai J, You S, Li X, et al. Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019. BMC Infect Dis. 2024 Feb 22;24(1):243.
Pedersen OS, Holmgaard FB, Mikkelsen MKD, Lange C, Sotgiu G, Lillebaek T, et al. Global treatment outcomes of extensively drug-resistant tuberculosis in adults: A systematic review and meta-analysis. J Infect. 2023 Sep;87(3):177–89.
Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9):a017863.
Parsons LM, Somoskövi Á, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, et al. Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and Opportunities. Clin Microbiol Rev. 2011 Apr;24(2):314.
Chen X, Ye J, Lei H, Wang C. Novel Potential Diagnostic Serum Biomarkers of Metabolomics in Osteoarticular Tuberculosis Patients: A Preliminary Study. Front Cell Infect Microbiol [Internet]. 2022 Mar 25 [cited 2024 Nov 21];12. Available from: https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2022.827528/full
Leo S, Narasimhan M, Rathinam S, Banerjee A. Biomarkers in diagnosing and therapeutic monitoring of tuberculosis: a review. Ann Med. 2024 Aug 3;56(1):2386030.
Wang C, Liu CM, Wei LL, Shi LY, Pan ZF, Mao LG, et al. A Group of Novel Serum Diagnostic Biomarkers for Multidrug-Resistant Tuberculosis by iTRAQ-2D LC-MS/MS and Solexa Sequencing. Int J Biol Sci. 2016 Jan 1;12(2):246.
Basingnaa A, Antwi-Baffour S, Nkansah DO, Afutu E, Owusu E. Plasma Levels of Cytokines (IL-10, IFN-γ and TNF-α) in Multidrug Resistant Tuberculosis and Drug Responsive Tuberculosis Patients in Ghana. Diseases. 2018 Dec 23;7(1):2.
Mensah GI, Boakye AN, Basingnaa A, Owusu E, Antwi-Baffour S, Ofori MF, et al. Identification of Serum Cytokine Biomarkers Associated with Multidrug Resistant Tuberculosis (MDR-TB). Immuno. 2021 Oct 30;1(4):400–9.
Sampath P, Rajamanickam A, Thiruvengadam K, Natarajan AP, Hissar S, Dhanapal M, et al. Cytokine upsurge among drug-resistant tuberculosis endorse the signatures of hyper inflammation and disease severity. Sci Rep. 2023 Jan 16;13(1):785.
Bartolomeu-Gonçalves G, Souza JM de, Fernandes BT, Spoladori LFA, Correia GF, Castro IM de, et al. Tuberculosis Diagnosis: Current, Ongoing, and Future Approaches. Diseases. 2024 Sep;12(9):202.
WHO. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis [Internet]. 2018 [cited 2024 Nov 21]. Available from: https://www.who.int/publications/i/item/9789241514842
WHO Regional Office for Europe. Algorithm for laboratory diagnosis and treatment-monitoring of pulmonary tuberculosis and drug-resistant tuberculosis using state-of-the-art rapid molecular diagnostic technologie. 2017.
Aricha SA, Kingwara L, Mwirigi NW, Chaba L, Kiptai T, Wahogo J, et al. Comparison of GeneXpert and line probe assay for detection of Mycobacterium tuberculosis and rifampicin-mono resistance at the National Tuberculosis Reference Laboratory, Kenya. BMC Infect Dis. 2019 Oct 15;19(1):852.
Farra A, Koula K, Jolly BL, Gando HG, Ouarandji LM, Mossoro-Kpinde CD, et al. Effectiveness of Xpert MTB/RIF and the Line Probe Assay tests for the rapid detection of drug-resistant tuberculosis in the Central African Republic. PLOS Glob Public Health. 2023 May 1;3(5):e0001847.
Osei Sekyere J, Maphalala N, Malinga LA, Mbelle NM, Maningi NE. A Comparative Evaluation of the New Genexpert MTB/RIF Ultra and other Rapid Diagnostic Assays for Detecting Tuberculosis in Pulmonary and Extra Pulmonary Specimens. Sci Rep. 2019 Nov 12;9(1):16587.
Drain PK, Gardiner J, Hannah H, Broger T, Dheda K, Fielding K, et al. Guidance for Studies Evaluating the Accuracy of Biomarker-Based Nonsputum Tests to Diagnose Tuberculosis. J Infect Dis. 2019 Oct 8;220(220 Suppl 3):S108–15.
WHO. High priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting [Internet]. 2014 [cited 2024 Nov 21]. Available from: https://www.who.int/publications/i/item/WHO-HTM-TB-2014.18
Kasule GW, Hermans S, Semugenze D, Wekiya E, Nsubuga J, Mwachan P, et al. Non-sputum-based samples and biomarkers for detection of Mycobacterium tuberculosis: the hope to improve childhood and HIV-associated tuberculosis diagnosis. Eur J Med Res. 2024 Oct 18;29(1):502.
Ocaña-Guzmán R, Téllez-Navarrete NA, Ramón-Luing LA, Herrera I, De Ita M, Carrillo-Alduenda JL, et al. Leukocytes from Patients with Drug-Sensitive and Multidrug-Resistant Tuberculosis Exhibit Distinctive Profiles of Chemokine Receptor Expression and Migration Capacity. Fernandes ES, editor. J Immunol Res. 2021 Apr 21;2021:1–19.
Bolajoko E, Arinola O, Odaibo G, Maiga M. Plasma levels of tumor necrosis factor-alpha, interferon-gamma, inducible nitric oxide synthase, and 3-nitrotyrosine in drug-resistant and drug-sensitive pulmonary tuberculosis patients, Ibadan, Nigeria. Int J Mycobacteriology. 2020;9(2):185.
Shi W, Wu J, Tan Q, Hu CM, Zhang X, Pan HQ, et al. Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients. Infect Drug Resist. 2019 May;Volume 12:1265–76.
Yang Y, Wu J. Significance of the Differential Peptidome in Multidrug-Resistant Tuberculosis. BioMed Res Int. 2019 Jan 17;2019:1–12.
Zhao J, Gao S, Chen C, Li H, Wang S, Yu Y, et al. Screening and identification of differentially expressed long non-coding RNAs in multidrug-resistant tuberculosis. PeerJ. 2022 Jan 17;10:e12776.
Ferrian S, Manca C, Lubbe S, Conradie F, Ismail N, Kaplan G, et al. A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis. Hoshino Y, editor. PLOS ONE. 2017 May 2;12(5):e0176660.
Carranza C, Herrera MT, Guzmán-Beltrán S, Salgado-Cantú MG, Salido-Guadarrama I, Santiago E, et al. A Dual Marker for Monitoring MDR-TB Treatment: Host-Derived miRNAs and M. tuberculosis-Derived RNA Sequences in Serum. Front Immunol. 2021 Nov 4;12:760468.
